NZ774254A - Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia - Google Patents
Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobiaInfo
- Publication number
- NZ774254A NZ774254A NZ774254A NZ77425416A NZ774254A NZ 774254 A NZ774254 A NZ 774254A NZ 774254 A NZ774254 A NZ 774254A NZ 77425416 A NZ77425416 A NZ 77425416A NZ 774254 A NZ774254 A NZ 774254A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- pacap
- antigen binding
- binding fragments
- photophobia
- Prior art date
Links
- 206010034960 Photophobia Diseases 0.000 title claims abstract 3
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 239000012634 fragment Substances 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 206010063659 Aversion Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This invention relates to anti-PACAP antibodies, and antigen binding fragments thereof, for use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.
Claims (4)
1. Use of an anti-PACAP antibody in the manufacture of a medicament for ameliorating or reducing the symptoms of, or treating, or preventing photophobia, light aversion or avoidance and sensitivity to light, wherein the anti-PACAP antibody comprises the heavy chain CDR sequences SEQ ID NO: 444; SEQ ID NO: 446; and SEQ ID NO: 448 and the light chain CDR sequences SEQ ID NO: 464; SEQ ID NO: 466; and SEQ ID NO: 468.
2. Use of claim 1, wherein the anti-PACAP comprises the Variable Heavy Chain of SEQ ID No: 442, and the Variable Light Chain of SEQ ID No: 462.
3. Use of claim 1, wherein the anti-PACAP comprises the Heavy Chain of SEQ ID No: 450 and the Light Chain of SEQ ID No: 470.
4. Use of any one of claims 1-3, substantially as herein described with reference to any example thereof and with or without reference to the figures.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148640P | 2015-04-16 | 2015-04-16 | |
| US201562148557P | 2015-04-16 | 2015-04-16 | |
| US201562148562P | 2015-04-16 | 2015-04-16 | |
| US201562148596P | 2015-04-16 | 2015-04-16 | |
| US201562148550P | 2015-04-16 | 2015-04-16 | |
| US201562148643P | 2015-04-16 | 2015-04-16 | |
| US201562148583P | 2015-04-16 | 2015-04-16 | |
| NZ736285A NZ736285A (en) | 2015-04-16 | 2016-04-15 | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ774254A true NZ774254A (en) | 2024-09-27 |
| NZ774254B2 NZ774254B2 (en) | 2025-01-07 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550023A1 (en) | Humanized anti-tau antibodies | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| MY205789A (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| MX2018009498A (en) | Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes. | |
| PE20210115A1 (en) | ANTI-TAU ANTIBODIES AND USE OF THEM | |
| NZ736285A (en) | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia | |
| MX2020009862A (en) | Pharmaceutical composition for treatment and/or prevention of cancer. | |
| WO2014186622A3 (en) | Methods of treatment for guillain-barre syndrome | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| WO2016029073A3 (en) | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| MD4716B1 (en) | Anti-LAG3 antibodies and antigen-binding fragments | |
| MX348579B (en) | Drug composition for cancer treatment and/or prevention. | |
| NZ630881A (en) | Use of semaphorin-4d binding molecules for treatment of atherosclerosis | |
| WO2019066435A3 (en) | Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same | |
| MX2015015110A (en) | Antibody specifically binding to her2. | |
| AU2018290532A1 (en) | Immunotherapy for hepatocellular carcinoma | |
| EP4445913A3 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| WO2019089753A3 (en) | Cd137 antibodies and pd-1 antagonists and uses thereof | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| AU2017269839A1 (en) | Methods for treatment of refractory generalized myasthenia gravis | |
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
| MX2022008471A (en) | Anti-angptl3 antibody and use thereof. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |